Replimune Group

Replimune

Replimune develops oncolytic immunotherapies for cancer patients, including an approved viral treatment for adults with advanced, treatment-resistant melanoma.

CMPI

This biopharmaceutical company develops cancer immunotherapies that activate the immune system to treat patients with advanced solid tumours, such as metastatic melanoma.

CG Oncology

This biopharmaceutical company develops oncolytic immunotherapies for patients with non-muscle invasive bladder cancer.

Cullinan Oncology

This company develops therapies for patients living with autoimmune diseases and cancer.

CARGO Therapeutics

This biotechnology company develops engineered cell therapies to treat cancer patients with relapsed or resistant lymphoma.

Humane Genomics

This company develops synthetic oncolytic viral therapies to treat cancer patients by engineering viruses that selectively infect and destroy malignant cells.

Targovax AS (Oncos)

This biotechnology company develops circular RNA therapeutics and oncolytic virus-based immunotherapies for patients with solid tumours and other difficult-to-treat diseases.

Theolytics

The company develops oncolytic viral immunotherapies for patients with solid tumours.